Floatz logo

Fludeoxyglucose

Chordoma

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Chordoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Sarcoma Oncology Research Center, LLC
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 1/2CCC
Tiragolumab
National Cancer Institute (NCI)
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Fludeoxyglucose is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →
prostate carcinomaActive
BB
Indicative · Phase 2/3
69 / 100
View asset →
breast carcinomaActive
BB
Indicative · Phase 2
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →